HQL
Tekla Life Sciences InvestorsNYSEFinancial ServicesAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
2.85
PEG
0.01
P/B
0.95
P/S
16.30
EV/EBITDA
5.68
DCF Value
$91.97
FCF Yield
-0.5%
Div Yield
11.3%
Margins & Returns
Gross Margin
30.8%
Operating Margin
286.9%
Net Margin
286.9%
ROE
18.8%
ROA
16.6%
ROIC
16.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $11.6M | $132.8M | $4.60 |
| FY 2025 | $86.4M | $85.6M | $2.96 |
| Q2 2025 | $18.2M | $-47.2M | $-1.64 |
| Q4 2024 | $1.9M | $35.0M | $1.22 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Financial Services
Industry
—
Country
US
Exchange
NYSE
Beta
0.74
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.